Advair
On November 15, 2005 the FDA issued a public health advisory about potentially fatal side effects from two GlaxoSmithKline asthma drugs. The FDA asked the drug maker Advair Diskus to add warning labels to Serevent and Advair indicating they “may increase the chance of severe asthma episodes, and death when those episodes occur”.
In one study, the agency says, “an increased number of people taking a LABA in addition to their usual asthma care died from their asthma compared to people taking a placebo in addition to their usual asthma care, although the number of asthma deaths in the study was small.”
In August 2003, the FDA announced the addition of new safety information and warnings to the labeling for drug products that contain salmeterol. The new labeling includes a boxed warning about a small, but significant, increased risk of life-threatening asthma episodes or asthma-related deaths observed in patients taking salmeterol in a recently completed large U.S. safety study.
Advair Label Update
On May 16, 2006, the FDA announced that the product label for Advair has been updated with a warning that the drug might well increase the chance of severe asthma attacks that can result in death.
Side effects of Advair may consist of the following: bronchitis, cough, vomiting, diarrhea, difficulty speaking, fungal infection of the mouth, headaches, stomach pain, hoarseness, muscle and bone pain, nausea, sore throat and sinus pain.
Call the offices of Evan D. Buxner today at 1-888-725-0503 or, email us for a free initial consultation to discuss your case and your rights under the law.
|
